[{"NetIncomeLoss_2_Q2_USD":-97316000.0,"WeightedAverageNumberOfShareOutstandingBasicAndDiluted_2_Q2_shares":45834305.0,"WeightedAverageNumberOfShareOutstandingBasicAndDiluted_1_Q2_shares":45876106.0,"InterestAndOtherIncome_2_Q2_USD":1600000.0,"InterestAndOtherIncome_1_Q2_USD":500000.0,"CommitmentsAndContingencies_0_Q2_USD":null,"AccruedLiabilitiesCurrent_0_Q2_USD":71886000.0,"InventoryFinishedGoodsNetOfReserves_0_Q2_USD":3022000.0,"AccumulatedOtherComprehensiveIncomeLossNetOfTax_0_Q2_USD":117000.0,"ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_0_Q2_USD":17178000.0,"NetCashProvidedByUsedInInvestingActivities_2_Q2_USD":73212000.0,"Depreciation_2_Q2_USD":3186000.0,"ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_2_Q2_shares":556133.0,"AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_0_Q2_USD":32000.0,"ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_0_Q2_USD":25.69,"AssetsCurrent_0_Q2_USD":313079000.0,"PaymentsToAcquireAvailableForSaleSecuritiesDebt_2_Q2_USD":43455000.0,"SellingGeneralAndAdministrativeExpense_2_Q2_USD":70139000.0,"SellingGeneralAndAdministrativeExpense_1_Q2_USD":33237000.0,"DebtInstrumentUnamortizedDiscount_0_Q2_USD":117093000.0,"CostOfGoodsAndServicesSold_2_Q2_USD":13418000.0,"CostOfGoodsAndServicesSold_1_Q2_USD":7326000.0,"AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_2_Q2_shares":9243003.0,"AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_1_Q2_shares":9243003.0,"StockIssuedDuringPeriodValueStockOptionsExercised_1_Q2_USD":119000.0,"StockIssuedDuringPeriodValueShareBasedCompensation_1_Q2_USD":295000.0,"CommonStockSharesIssued_0_Q2_shares":46513349.0,"InventoryWorkInProcessNetOfReserves_0_Q2_USD":14037000.0,"AvailableForSaleSecuritiesDebtSecurities_0_Q2_USD":90619000.0,"OtherNoncashIncomeExpense_2_Q2_USD":-7000.0,"Assets_0_Q2_USD":385255000.0,"ConvertibleLongTermNotesPayable_0_Q2_USD":199157000.0,"OperatingLeaseLiability_0_Q2_USD":15815000.0,"ResearchAndDevelopmentExpense_2_Q2_USD":39116000.0,"ResearchAndDevelopmentExpense_1_Q2_USD":19943000.0,"ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_0_Q2_USD":28.09,"AdjustmentForAmortization_2_Q2_USD":13358000.0,"AssetsFairValueDisclosure_0_Q2_USD":241918000.0,"OtherNonoperatingIncomeExpense_2_Q2_USD":-10856000.0,"OtherNonoperatingIncomeExpense_1_Q2_USD":-5634000.0,"AccountsReceivableNetCurrent_0_Q2_USD":43078000.0,"IncomeTaxExpenseBenefit_2_Q2_USD":-33000.0,"IncomeTaxExpenseBenefit_1_Q2_USD":0.0,"CommonStockValue_0_Q2_USD":47000.0,"NetCashProvidedByUsedInFinancingActivities_2_Q2_USD":-1160000.0,"CostsAndExpenses_2_Q2_USD":124867000.0,"PreferredStockSharesOutstanding_0_Q2_shares":0.0,"CostsAndExpenses_1_Q2_USD":60586000.0,"PaymentsOfStockIssuanceCosts_2_Q2_USD":1160000.0,"ProceedsFromIssuanceOfDebt_2_Q2_USD":8274000.0,"CashCashEquivalentsAndShortTermInvestments_0_Q2_USD":241918000.0,"IncreaseDecreaseInInventories_2_Q2_USD":-2397000.0,"ComprehensiveIncomeNetOfTax_2_Q2_USD":-97107000.0,"ComprehensiveIncomeNetOfTax_1_Q2_USD":-47950000.0,"OtherAssetsNoncurrent_0_Q2_USD":1093000.0,"CashAndCashEquivalentsAtCarryingValue_0_Q2_USD":151299000.0,"OperatingLeaseLiabilityNoncurrent_0_Q2_USD":10501000.0,"ProceedsFromSaleMaturityAndCollectionsOfInvestments_2_Q2_USD":118357000.0,"Liabilities_0_Q2_USD":295443000.0,"OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_2_Q2_USD":209000.0,"OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_1_Q2_USD":237000.0,"IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities_2_Q2_USD":1484000.0,"ShortTermInvestments_0_Q2_USD":90619000.0,"ShareBasedCompensation_2_Q2_USD":20705000.0,"ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_2_Q2_USD":41.62,"IncreaseDecreaseInAccountsReceivable_2_Q2_USD":4724000.0,"CommonStockSharesOutstanding_0_Q2_shares":46513349.0,"InvestmentsFairValueDisclosure_0_Q2_USD":90619000.0,"AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_0_Q2_USD":13781000.0,"AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_0_Q2_USD":147000.0,"IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2_Q2_USD":-97349000.0,"IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1_Q2_USD":-48187000.0,"AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_1_Q2_USD":10289000.0,"NetCashProvidedByUsedInOperatingActivities_2_Q2_USD":-64693000.0,"InventoryRawMaterialsNetOfReserves_0_Q2_USD":2033000.0,"RepaymentsOfDebt_2_Q2_USD":8274000.0,"ProceedsFromWarrantExercises_2_Q2_USD":0.0,"LiabilitiesCurrent_0_Q2_USD":83861000.0,"CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2_Q2_USD":7359000.0,"AccountsPayableCurrent_0_Q2_USD":6661000.0,"PrepaidExpenseAndOtherAssetsCurrent_0_Q2_USD":8991000.0,"CashAndCashEquivalentsFairValueDisclosure_0_Q2_USD":151299000.0,"OtherAccruedLiabilitiesCurrent_0_Q2_USD":3506000.0,"AdditionalPaidInCapital_0_Q2_USD":1082964000.0,"ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_0_Q2_USD":0.05,"StockIssuedDuringPeriodSharesStockOptionsExercised_2_Q2_shares":43676.0,"NumberOfOperatingSegments_2_Q2_Segment":1.0,"PreferredStockSharesIssued_0_Q2_shares":0.0,"CapitalExpendituresIncurredButNotYetPaid_2_Q2_USD":409000.0,"ProceedsFromPaymentsForOtherFinancingActivities_2_Q2_USD":0.0,"SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_0_Q2_USD":17066000.0,"PropertyPlantAndEquipmentNet_0_Q2_USD":56177000.0,"NetIncomeLoss_1_Q2_USD":-48187000.0,"PaymentsOfDebtIssuanceCosts_2_Q2_USD":0.0,"OperatingLeaseRightOfUseAsset_0_Q2_USD":14906000.0,"RetainedEarningsAccumulatedDeficit_0_Q2_USD":-993316000.0,"ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_0_Q2_shares":8628753.0,"PreferredStockParOrStatedValuePerShare_0_Q2_USD":0.001,"CommonStockParOrStatedValuePerShare_0_Q2_USD":0.001,"DebtInstrumentFaceAmount_0_Q2_USD":316250000.0,"IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_2_Q2_USD":861000.0,"CommonStockSharesAuthorized_0_Q2_shares":150000000.0,"RevenueFromContractWithCustomerExcludingAssessedTax_2_Q2_USD":38374000.0,"RevenueFromContractWithCustomerExcludingAssessedTax_1_Q2_USD":18033000.0,"OperatingIncomeLoss_2_Q2_USD":-86493000.0,"OperatingIncomeLoss_1_Q2_USD":-42553000.0,"InventoryNet_0_Q2_USD":19092000.0,"ContractWithCustomerLiabilityCurrent_0_Q2_USD":47149000.0,"ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_2_Q2_USD":19.2,"PreferredStockValue_0_Q2_USD":0.0,"ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_0_Q2_shares":5945696.0,"ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_2_Q2_USD":6.59,"EmployeeRelatedLiabilitiesCurrent_0_Q2_USD":9750000.0,"PreferredStockSharesAuthorized_0_Q2_shares":15000000.0,"AllocatedShareBasedCompensationExpense_2_Q2_USD":20705000.0,"AllocatedShareBasedCompensationExpense_1_Q2_USD":10176000.0,"ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_2_Q2_shares":309255.0,"PropertyPlantAndEquipmentGross_0_Q2_USD":69958000.0,"OperatingLeaseLiabilityCurrent_0_Q2_USD":5314000.0,"EarningsPerShareBasicAndDiluted_2_Q2_USD":-2.12,"EarningsPerShareBasicAndDiluted_1_Q2_USD":-1.05,"OtherLiabilitiesNoncurrent_0_Q2_USD":1924000.0,"StockholdersEquity_0_Q2_USD":89812000.0,"PaymentsToAcquirePropertyPlantAndEquipment_2_Q2_USD":1690000.0,"AvailableForSaleDebtSecuritiesAmortizedCostBasis_0_Q2_USD":90504000.0,"LiabilitiesAndStockholdersEquity_0_Q2_USD":385255000.0,"AccruedProfessionalFeesCurrent_0_Q2_USD":3002000.0,"Ticker":"AERI","CIK":"1337553","name":"AERIE PHARMACEUTICALS INC","OfficialName":"Aerie Pharmaceuticals Inc. Common Stock","form":"10-Q","period":"20200630","fy":"2020.0","fp":"Q2","qtrs":"2","uom":"USD","footnote":"nan","Market Cap":"408427417.0","Country":"United States","Sector":"Health Care","Industry":"Biotechnology: Biological Products (No Diagnostic Substances)","Market":"NASDAQ","SP500":"nan","filed":"20200807"}]